GlaxoSmithKline: Depressive Disorder trials

The registry lists 39 Depressive Disorder studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 25Phase 2 6Phase 3 2Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Paxil CR Bioequivalence Study Brazil - Fed AdministrationCompletedNCT01339247Phase 1Results posted
• Paxil CR Bioequivalence Study BrazilCompletedNCT01316926Phase 1Results posted
• Carcinogenicity Study of BupropionCompletedNCT01077596Results posted
• Safety and Efficacy Study in Patients With Major Depressive DisorderCompletedNCT00896363Phase 2Results posted
• A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderTerminatedNCT00880048Phase 2Results posted
• Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)CompletedNCT00866294Phase 3Results posted
• Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)TerminatedNCT00812812Phase 4Results posted
• MDD POC Study GSK372475 Subjects Depressive DiseaseCompletedNCT00420641Phase 2Results posted
• Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake InhibitorsCompletedNCT00296517Phase 3Results posted
• Study Of 323U66 SR In Major Depressive DisorderCompletedNCT00135512Phase 2Results posted
• Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome PatientsWithdrawnNCT01916200Phase 4
• Bupropion & Cardio Birth Defect (Slone)CompletedNCT01597661
• A PET Study in Healthy VolunteersCompletedNCT01424449Phase 1
• Emotional Processing in Healthy Volunteers in the Presence of an Investigational AnxiolyticCompletedNCT01424384Phase 1
• Bupropion and Specific Cardiovascular MalformationsCompletedNCT01165255
• An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET LigandsCompletedNCT01153802Phase 1
• Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy SubjectsCompletedNCT01090440Phase 1
• First Study in Humans With GSK424887CompletedNCT01059591Phase 1
• First Study in Humans With GSK206136CompletedNCT01059578Phase 1
• First Time in Human StudyCompletedNCT01031186Phase 1
• Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male SubjectsCompletedNCT01000857Phase 1
• Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male SubjectsCompletedNCT00938184Phase 1
• Food and Relative Bioavailability StudyCompletedNCT00843011Phase 1
• PAXIL CR Bioequivalence StudyCompletedNCT00749359Phase 1
• GSK372475 PK Study in Healthy VolunteersCompletedNCT00728208Phase 1
• A First Time in Human Study of GSK586529 in Healthy VolunteersCompletedNCT00703547Phase 1
• Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female VolunteersCompletedNCT00536679Phase 1
• A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy VolunteersCompletedNCT00513565Phase 1
• 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)CompletedNCT00511654Phase 1
• GSK372475 Bioequivalence StudyCompletedNCT00488098Phase 1
• A Study Of New Medicine (GSK 372475) For The Treatment Of DepressionCompletedNCT00448058Phase 2
• A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular PressureCompletedNCT00439868Phase 1
• Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy MalesCompletedNCT00435695Phase 1
• To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.CompletedNCT00426608Phase 1
• A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese SubjectsCompletedNCT00406432Phase 1
• Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese SubjectsCompletedNCT00406003Phase 1
• PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety PatientsCompletedNCT00343707Phase 2
• GW679769 In FibromyalgiaCompletedNCT00264628
• Seasonal Affective Depression (SAD) StudyCompletedNCT00069459Phase 1